Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: Potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment

التفاصيل البيبلوغرافية
العنوان: Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: Potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment
المؤلفون: Carmen Ruggiero, Giorgio Arnaldi, Vincenzo Pezzi, Rosa Sirianni, Adele Chimento, Lidia Cerquetti, Francesco Fallo, Catia Pilon, Antonio Stigliano, Giulia Carpinelli, Fabiana Zolea
بيانات النشر: ENDOCRINE SOC, 2012.
سنة النشر: 2012
مصطلحات موضوعية: Selective Estrogen Receptor Modulators, medicine.medical_specialty, Antineoplastic Agents, Hormonal, medicine.drug_class, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Down-Regulation, Mice, Nude, Estrogen receptor, Biochemistry, Mice, Endocrinology, adrenal tumors, Cell Line, Tumor, Internal medicine, medicine, Animals, Humans, Adrenocortical carcinoma, Molecular Targeted Therapy, Aromatase, Estrogen receptor beta, Cell Proliferation, oestrogen receptors, biology, Cell growth, Carcinoma, Biochemistry (medical), Estrogen Receptor alpha, medicine.disease, Xenograft Model Antitumor Assays, Adrenal Cortex Neoplasms, Gene Expression Regulation, Neoplastic, Selective estrogen receptor modulator, Estrogen, biology.protein, Female, Estrogen receptor alpha
الوصف: Adrenocortical carcinoma (ACC) is a rare tumor with a very poor prognosis and no effective treatment. ACC is characterized by an increased production of IGF-II and by estrogen receptor (ER)-α up-regulation.The objective of this study was to define the role played by ERα in 17β-estradiol (E2)- and IGF-II-dependent ACC growth and evaluate whether selective estrogen receptor modulators are effective in controlling ACC growth in vivo.The human adrenocortical cell line H295R was used as an in vitro model and to generate xenograft tumors in athymic nude mice.In H295R cells IGF-II controlled expression of steroidogenic factor-1 that, in turn, increased aromatase transcription and, consequently, estrogen production, inducing cell proliferation. ERα silencing significantly blocked E2- and IGF-II-dependent cell proliferation. This effect was dependent on the regulation of cyclin D1 expression by ERα, activated in response to both E2 and IGF-II. In fact, IGF-II induced ERα activation by phosphorylating serine 118 and 167. Furthermore, we demonstrated that ERα mediated E2-induced nongenomic signaling that stimulated IGF-I receptor (IGF1R), ERK1/2, and AKT phosphorylation, resulting in a ligand-independent activation of the IGF1R-induced pathway. In addition, E2 potentiated this pathway by up-regulating IGF1R expression as a consequence of increased cAMP-responsive element binding protein activation and binding to IGF1R promoter. The estrogen antagonist, hydroxytamoxifen, the active metabolite of tamoxifen, reduced IGF1R protein levels and both E2- and IGF-II-induced cell proliferation. Moreover, H295R xenograft growth was strongly reduced by tamoxifen.These findings establish a critical role for ERα in E2- and IGF-II-dependent ACC proliferation and provide a rationale for targeting ERα to control the proliferation of ACC.
اللغة: English
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d68f697e36def8463dfdd88237e70d8Test
http://hdl.handle.net/11573/673226Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....4d68f697e36def8463dfdd88237e70d8
قاعدة البيانات: OpenAIRE